Pricing changes, provider updates, and policy changes across telehealth.
July 31, 2026
FDA Advisory Panel Recommends Compounding of BPC-157 and 5 Other Peptides — But They're Still Not Legal
An FDA advisory committee voted to recommend six unapproved peptides for the 503A Bulks List, including BPC-157 and TB-500. The vote is non-binding — none are legal to compound today.
Read →
August 2, 2026
RENVA Publishes First GLP-1 Telehealth Cost Report — Real Cost Runs $33/Month Above Advertised Price
RENVA's first Telehealth Cost Report finds the average advertised GLP-1 starting price is $147/month, while the average true monthly cost runs $180/month — a $33 gap across 33 providers.
Read →
June 30, 2026
RENVA News: Tracking Telehealth Pricing and Policy Changes
RENVA is launching a news section to track provider pricing changes, policy updates, and industry developments across all 8 telehealth verticals.
Read →